Clinical Trials · NCT02617654
Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Per-Ola Carlsson
- Enrollment
- 18
- Start date
- Nov 2015
- Locations
- 1 site, Sweden
- Primary endpoint
- The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production